The Role of Sialic Acid in the Dysfibrinogenemia Associated With Liver Disease: Distribution of Sialic Acid on the Constituent Chains

By Jose Martinez, Karen A. MacDonald, and Joseph E. Palascak

To further evaluate the role of sialic acid in the dysfibrinogenemia associated with liver disease, we studied the effect of removal of excess sialic acid residues from the fibrinogen of five patients with liver disease on the thrombin time and fibrin monomer aggregation. Patient fibrinogens containing 1.4–3.4 residues of sialic acid per molecule in excess of normal controls, with thrombin times 12–22 sec longer than normal and with abnormal fibrin monomer aggregation, were stripped of their excess sialic acid by incubation with Vibrio cholerae neuraminidase, followed by rapid removal of the enzyme by antineuraminidase antibody affinity chromatography. These partially desialylated patient fibrinogens, with a normal number of sialic acid residues remaining, exhibited normal thrombin times and normal fibrin monomer aggregation. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of reduced normal, patient, and partially desialylated patient (sialyl-\(^{3}H\))-fibrinogen exhibited 60% of the radioactivity in the B\(\beta\) chain and 40% in the \(\gamma\) chain. There was no radioactivity detectable in the A\(\alpha\) chain. These studies provide additional evidence that the increased sialic acid content of the acquired dysfibrinogenemia of liver disease is responsible for its functional defect and that the excess sialic acid is distributed on the B\(\beta\) chain and \(\gamma\) chains of the fibrinogen.

**THE DYSFIBRINOGENEMIA** associated with liver disease has been shown to be due to impaired fibrin monomer polymerization,1,2 which correlates with an increase in the sialic acid content of the protein.3,4 Complete desialylation of this abnormal fibrinogen results in an asialo derivative whose thrombin time is shortened to that of normal asialofibrinogen.5 To further characterize the role of sialic acid in this functional abnormality, we studied the effects of the removal of excess sialic acid residues from this fibrinogen on its thrombin time and fibrin monomer polymerization. In addition, the distribution of tri- tium-labeled sialic acid on the A\(\alpha\), B\(\beta\), and \(\gamma\) chains of normal and abnormal fibrinogens and of the partially desialylated abnormal fibrinogens was studied on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the reduced fibrinogens.

**MATERIALS AND METHODS**

**Patients**

The patients chosen for the present study were selected by the same clinical and laboratory criteria employed in patient selection in our previously reported study of the dysfibrinogenemia of liver disease.1 Patient plasma thrombin times were at least 50% longer than normal controls in the absence of clinical and laboratory evidence of disseminated intravascular coagulation and/or fibrinolysis.1 Three patients had alcoholic liver disease and two had postnecrotic cirrhosis of undetermined etiology. The abnormal patient fibrinogens were functionally characterized as previously described and exhibited the biochemical and functional properties of the dysfibrinogenemia of liver disease.1,3

**Purification of Fibrinogen**

Blood was collected with plastic syringes into 1/9 vol 3.8% sodium citrate, with epsilon-aminocaproic acid (EACA) added to give a final concentration of 0.1 M in the anticoagulated plasma. Samples were centrifuged at 2,500 g for 15 min. The platelet-poor plasma was separated and tested immediately or quick frozen and stored at –80°C. Fibrinogen was purified from normal and patient plasmas by the glycine precipitation method of Kazal et al.,3 modified by the addition of EACA to a final concentration of 0.1 M in plasmas and buffers. The concentration of fibrinogen present in the purified material was measured spectrophotometrically at 280 nm using an A\(\text{mg}^{-1}\) of 15.1.6 The recovery of fibrinogen from normal and abnormal plasmas ranged between 55% and 75%, and the purified fibrinogen was 96% clottable.

**Sialic Acid Studies**

Total sialic acid content of fibrinogen was measured by the thiobarbituric acid method after acid hydrolysis7 or after enzymatic cleavage with *Vibrio cholerae* neuraminidase (Behringwerke A.G., Marburg/Lahn, West Germany) in 0.15 M NaCl, 0.008 M CaCl\(_2\), pH 6.2, at 37°C for 3 hr.8 To obtain partially desialylated patient fibrinogens from which only the excess sialic acid was removed, 3 mg of fibrinogen was incubated with 50 U of neuraminidase under these same conditions, except that the incubation was limited to 1.5–2.5 min, depending on the amount of sialic acid to be cleaved.8 We had previously demonstrated that the initial release of sialic acid by neuraminidase under these conditions was rapid.4 By varying the time of incubation and by employing neuraminidase antibody affinity chromatography to rapidly remove neuraminidase from the reaction mixture, we were able, by trial and error, to obtain the degree of fibrinogen desialylation desired.

Rabbit antineuraminidase antibody was produced by injecting New Zealand white rabbits subcutaneously with *Vibrio cholerae* neuraminidase mixed with Freund's adjuvant. The immunized rabbit's serum was treated with 40% saturated (NH\(_4\))\(_2\)SO\(_4\) solution. The precipitate was dissolved in 0.15 M NaCl, precipitated a second time with (NH\(_4\))\(_2\)SO\(_4\), redissolved in 0.15 M NaCl, and dialyzed exten-
sively against 0.15 M NaCl. The neutralizing capacity of this frac
tion was tested by incubating 0.1 ml with 50 U of *Vibrio cholerae*
neuraminidase for 30 min. One milligram of normal fibrinogen and
CaCl$_2$ were then added to the mixture. The incubation was
continued for 2.5 hr, and released sialic acid residues were mea-
sured.$^6$ Nonimmunized rabbit serum was used in parallel control
experiments. Rabbit antineuraminidase antibody was linked to
cyanogen-bromide-activated Sepharose (Pharmacia Fine Chemi-
incubation mixtures were rapidly passed through a 2-ml immuno-
sorbent column. Of the fibrinogens applied to the immunoabsorbent
column, 85%–90% was recovered in the column eluate. The fibrin-
ogen sialic acid residues were measured in column eluates after acid
hydrolysis by the thiobarbituric acid method immediately after
collection. To determine whether biologically active neuraminidase
remained in the eluates after antibody affinity chromatography, the
eluates were incubated for 24 hr at pH 6.0 after the addition of
CaCl$_2$, and sialic acid residues were measured as indicated above.
Normal fibrinogen was treated in an identical manner, except that
neuraminidase was omitted from the incubation mixtures. The sialic
acid residues released by neuraminidase in the incubation step may
have become bound to the immunoabsorbent column or may have
been lost during extensive dialysis of the eluates prior to the
measurement of the sialic acid content of the fibrinogens and the
performance of the functional studies.

**Preparation of (Sialyl-3H)-Fibrinogen**

The sialic acid residues of normal, patient, and partially desialy-
lated patient fibrinogens were labeled with tritium by the method of
Van Lenten and Ashwell.$^8$ Ten milligrams of fibrinogen in 0.1 M
sodium acetate, 0.15 M NaCl, pH 6.0, were oxidized by the addition
of sodium metaperiodate in 10 M excess with respect to sialic acid.
The reaction was stopped by the addition of ethylene glycol, and the
oxidized fibrinogens were reduced with tritiated sodium borohydride
(specific activity 555 mCi/mmole, Amersham Corporation, Arling-
ton Heights, IL) followed by the addition of excess cold sodium
borohydride.$^9$ The labeled fibrinogen were then precipitated with
glycine at 20°C.$^1$ The precipitates were dissolved in 0.055 M sodium
citrate, pH 7.4, and dialyzed extensively against this buffer. To
measure the amount of radioactivity incorporated, fibrinogen was
clotted with bovine thrombin (Parke, Davis and Co., Detroit, Ml) in
the presence of 0.08%, was clotted with 4 U of human thrombin for 3 hr at 37°C.
Highly purified human thrombin was obtained through the courtesy
of Dr. John Fenton, New York State Department of Health Labora-
tories, Albany, NY. The clots were recovered on a glass rod, washed
3 times with 0.15 M NaCl, and dissolved in 0.02 M acetic acid. One
volume of monomer was mixed with 10 vol of 0.06 M sodium
phosphate, pH 6.8, and allowed to aggregate for 3 hr at 4°C. The
clots were then recovered, washed, and dissolved in acetic acid as
described above. To 0.1 ml of the fibrin monomer solution at a
concentration of 1.2 mg/ml in a cuvette was added 1.1 ml of 0.06 M
sodium phosphate, pH 6.8, ion strength 0.12, and the aggregation
of the fibrin monomers was followed by measuring absorbance at
350 nm over 30 min in a Gilford spectrophotometer with an
automatic cuvette positioner (Gilford Instrument Laboratories, Inc.,
Obelin, OH). Fibrin monomer aggregation was also studied at an
ion strength of 0.24 by adjusting the ionic strength of the
phosphate buffer with NaCl.$^6$

**Electrophoretic Studies**

SDS-PAGE of 5 normal and 5 patient purified fibrinogens
reduced with β-mercaptoethanol was performed as previously
described.$^9$ Densitometric scans of the Coomassie-blue-stained gels
were made with a Gilford gel scanner. Gels of the reduced normal
and patient neuraminidase-treated fibrinogens were also scanned.
Normal, patient, and partially desialylated patient (sialyl-3H)-
fibrinogens were also reduced and run in SDS-PAGE. The gels were
cut into 1-mm slices, and the protein was eluted with 6 M guanidi-
num chloride at 90°C overnight. The eluates were mixed with 15 ml
of Triton X-100–toluene scintillation cocktail,$^{1,17}$ and radioactivity
was measured in a Packard liquid scintillation spectrometer.

**RESULTS**

All patient fibrinogens studied had increased sialic acid
contents ranging from 1.4 to 3.4 residues per
molecule in excess of normal fibrinogen (Fig. 1).

**Neutralization Studies**

A 0.1-ml aliquot of the rabbit antineuraminidase
antibody fraction neutralized the activity of 50 U of
*Vibrio cholerae* neuraminidase in incubation studies.
*Vibrio cholerae* neuraminidase treated with nonimmu-
ized rabbit serum antibody fraction, on the other
hand, retained its enzymatic effect, releasing 5.2 sialic
acid residues from fibrinogen over the period of incu-
Bation. In addition, patient fibrinogen–neuraminidase
biochemistry. The supernatants after treatment of the labeled fibrinogens with a 3-vol
0.15M NaCl, pH 7.4, prior to determination of their thrombin times.

Fibrin monomer aggregation was studied by a modification of the
method of Belitzer et al.$^{1,4,15}$ One and two-tenths milliliter of a
solution of fibrinogen at a concentration of 1.0 mg/ml in 0.06 M
sodium phosphate, pH 6.8, with EDTA at a final concentration of
0.08%, was clotted with 4 U of human thrombin for 3 hr at 37°C.

For personal use only.on October 3, 2017. For personal use only.
incubation mixtures retained no detectable enzymatic activity after one passage through antineuraminidase antibody affinity columns. Samples tested immediately after chromatography and again 24 hr following chromatography had the same number of sialic acid residues per molecule. Incubation of patient fibrinogens with neuraminidase followed by rapid removal of the enzyme by antineuraminidase antibody affinity chromatography produced partially desialylated derivatives with normal numbers of sialic acid residues (Fig. 1).

Functional Studies of Fibrinogen

The thrombin times of the patient fibrinogens with full sialic acid complements ranged from 12 sec to 22 sec longer than the normal controls. Patient 3 fibrinogen, the most abnormal fibrinogen studied, had a thrombin time of 44 sec. Removal of 3.1 residues of sialic acid per molecule from this fibrinogen resulted in a derivative with a normal number of sialic acid residues and a thrombin time of 23 sec (Fig. 1). In like manner, removal of excess sialic acid residues of the other four patient fibrinogens studied resulted in normalization of their thrombin times (Fig. 1). When partial desialylation resulted in removal of more than the excess number of sialic acid residues, the thrombin times of these partially desialylated fibrinogens were correspondingly shorter than the normal controls. Normal fibrinogen incubated as above, except that neuraminidase was eliminated from the incubation mixture, had a normal thrombin time before and after immunoadsorbent column chromatography.

The aggregation of fibrin monomers prepared from normal, patient, and partially desialylated patient fibrinogens is shown in Fig. 2. Patient fibrinogens with full sialic acid complements demonstrated impaired rate of onset and total extent of monomer aggregation as compared to controls (Fig. 2A). Removal of the excess sialic acid residues resulted in normalization of the monomer aggregation (Fig. 2B). Similar results were obtained in studies done at an ionic strength of 0.24. The sialic acid content of two partially desialylated patient fibrin monomer preparations was measured, and the monomers were found to have the same sialic acid content as the partially desialylated fibrinogen from which they were derived.

(Sialyl-1H)-Fibrinogen Studies

Normal and patient fibrinogens were labeled with 1H-borohydride, and the radioactivity was expressed as cpm/mg of protein. Partially desialylated patient fibrinogens with sialic acid contents approximating that of normal fibrinogen were also labeled. The results of these studies are shown in Table I. Normal (sialyl-1H)-fibrinogen contained $8.7 \times 10^5$ cpm/mg of protein, while patient fibrinogens that had 1.4–3.4 residues of sialic acid per molecule of protein in excess of normal controls incorporated more of the radioactive label. Partial desialylation resulted in a decrease in incorporation of the radioactive label by patient fibrinogens.

The thrombin clottability of the labeled control and patient fibrinogens was normal, with 96% of the radioactivity present in the clot. Similar results were obtained with TCA precipitation. The radioactive label was shown to be restricted to the sialic acid analogues of fibrinogen by acid hydrolysis and enzymatic cleavage studies. Ninety-five to ninety-six percent of the radioactivity was released by acid hydrolysis with only 4%–5% of the radioactivity remaining with the protein. Enzymatic cleavage resulted in release of 85% of the protein's radioactivity.

The $1H$-labeled sialic acid analogues released from (sialyl-1H)-fibrinogen by acid hydrolysis were studied...
DYSFIBRINOGENEMIA OF LIVER DISEASE

Fig. 2. Aggregation of fibrin monomers of purified normal and patient fibrinogens. Shaded areas represent the range of aggregation of five normal controls. The dashed lines represent the fibrin monomer aggregation of five patient fibrinogens with their full sialic acid complement [A] and after removal of their excess sialic acid [B] (ionic strength).

Reduced normal, patient, and partially desialylated patient (sialyl-\(^{1}H\))-fibrinogens run in SDS-PAGE demonstrated the presence of radioactivity in the B\(\beta\) and \(\gamma\) chains only, with no radioactivity detectable in the A\(\alpha\) chain (Fig. 3). In both normal and patient fibrinogen, 60% of the radioactivity was present in the B\(\beta\) chain and 40% was present in the \(\gamma\) chain. The partially desialylated patient fibrinogen showed a similar distribution of radioactivity between the B\(\beta\) and \(\gamma\) chains. Gels run in parallel and stained with Coomassie blue revealed normal mobility and amount of A\(\alpha\), B\(\beta\), and \(\gamma\) chains, with no evidence of proteolysis.

The biologic properties of normal, patient, and partially desialylated patient fibrinogens appeared to be unaffected by the \(^{1}H\)-borohydride labeling process, as the thrombin times of the labeled proteins were the same as those of the respective unlabeled proteins.

**DISCUSSION**

The dysfibrinogenemia associated with liver disease has been functionally characterized by a prolongation of the thrombin time due to impaired fibrin monomer polymerization. A\(\alpha\) This abnormally fibrinogen has an increased sialic acid content, and this increase in sialic acid correlates with the prolongation of the thrombin time. In addition, complete desialylation of the protein results in an asialo-derivative whose thrombin time is the same as that of control normal asialofibrinogen. In the present study, partially desialylated fibrinogens from patients with liver disease were prepared by incubating the proteins with *Vibrio cholerae* neuraminidase and rapidly removing the enzyme from the incubation mixture by passing it through an anti-neuraminidase antibody immunoadsorbent column. Employing this technique, we were able to prepare patient fibrinogens from which only the excess sialic acid residues were removed. Immunoadsorbent column chromatography per se had no effect on the biologic properties of fibrinogen in control studies. Removal of the excess sialic acid from patient fibrinogens resulted in normalization of their thrombin times.

**Table 1. Sialic Acid Labeling Studies**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Sialic Acid Residues/ Mol Fibrinogen</th>
<th>Sialyl-(^{1}H) Fibrinogen (cpm)/ mg Fibrinogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control†</td>
<td>60.0 ± 3</td>
<td>8.7 (\times) 10^5 ± 1.5 (\times) 10^5</td>
</tr>
<tr>
<td>Patient 1</td>
<td>8.0</td>
<td>12.0 (\times) 10^5</td>
</tr>
<tr>
<td>Patient 2</td>
<td>5.4</td>
<td>8.3 (\times) 10^5</td>
</tr>
<tr>
<td>Patient 3</td>
<td>3.0</td>
<td>1.35 (\times) 10^6</td>
</tr>
<tr>
<td>Patient 4</td>
<td>9.5 (\times) 10^5</td>
<td></td>
</tr>
<tr>
<td>Patient 5</td>
<td>7.4</td>
<td>12.0 (\times) 10^5</td>
</tr>
<tr>
<td>Patient 6</td>
<td>5.0</td>
<td>6.5 (\times) 10^5</td>
</tr>
</tbody>
</table>

* Sialic acid residues were measured after acid hydrolysis by the thiobarbituric acid assay, as previously described.
† Six normal fibrinogens. The control is expressed as the mean ± 1 SD.
** Indicates partially desialylated patient fibrinogens.
and their fibrin monomer polymerization. These studies indicate that the excess sialic acid content is responsible for the functional defect of this dysfibrinogenemia.

Normal and patient fibrinogens were also labeled with $^3$H-borohydride. The label was shown to be incorporated into sialic acid analogues on the fibrinogen as acid hydrolysis, which is known to cleave sialic acid under the conditions employed, and caused release of 95% of the protein's radioactivity. A lesser amount of radioactivity was released by neuraminidase treatment, because the sialic acid analogues present after labeling are a less suitable substrate for cleavage by neuraminidase. The radioactivity was recoverable as labeled sialic acid analogues as shown by resin chromatography and resorcinol assay of the radioactive peaks. The labeling procedure did not alter the biologic properties of the proteins as reflected in their thrombin times. SDS-PAGE of the reduced normal and patient (sialyl-$^3$H)-fibrinogens demonstrated restriction of the label to the $B\beta$ and $\gamma$ chains, with no radioactivity present on the $A\alpha$ chain. A similar distribution of radioactivity between the $B\beta$ and $\gamma$ chains was also observed when the partially desialylated patient fi-
DYSFIBRINOGENEMIA OF LIVER DISEASE

1201

Fibrinogens were labeled with tritium and reduced, indicating that neuraminidase removed proportional amounts of sialic acid from the Bβ and γ chains. These findings are consistent with previous reports that indicate that the carbohydrate moiety of fibrinogen is attached to Asn 364 of the B chain and to Asn 52 of the γ chain. The tripeptide sequence Asn-X-Thr/Ser, which serves as the site of carbohydrate attachment in plasma glycoproteins, occurs only once in the Bβ and γ chains. The increased sialic acid content of the Bβ chain as compared to the γ chain found in our studies is consistent with previous reports. The increased sialic acid present in the Bβ and γ chains of patients with liver disease may reflect an alteration in the primary structure of the peptide sequence of these chains, resulting in the presence of additional sites for carbohydrate attachment. However, it is more likely that the alteration occurs in the branching of the oligosaccharide chain itself, resulting in an increased number of sialic acid as well as galactose residues per chain.

Subpopulations of Bβ and γ chains, which differ in their sialic acid contents, have been demonstrated in studies with reduced and carboxymethylated human fibrinogen. In addition, studies of the isolated γ chains of bovine fibrinogen demonstrate heterogeneity based on differences in carbohydrate content. While earlier studies indicated that carbohydrate was present on the Aα chain, more recent studies, including our own, failed to demonstrate the presence of carbohydrate on the Aα chain by periodic acid-Schiff reagent staining of the reduced fibrinogens run in SDS-PAGE. Furthermore, after labeling of fibrinogen sialic acid with tritium, no or negligible radioactivity was detectable in the Aα chain after reduction and separation of the chains by electrophoresis, as in the present study, or by chromatographic techniques. A recent report of the completed sequence of the Aα chain indicates that two asparagine residues, Asn 269 and Asn 400, are in proper tripeptide sequence, i.e., Asn-X-Ser, to theoretically serve as possible sites for attachment of carbohydrate. Not all of the asparagine residues in glycoproteins that are in the appropriate tripeptide sequence, however, have attached carbohydrate. In such cases, it may be that the folding of the nascent polypeptide prevents the availability of these sites for carbohydrate attachment.

Similar alterations of the carbohydrate content of several plasma glycoproteins have been described in patients with hepatoma. The dysfibrinogenemia associated with hepatoma has been demonstrated to have an increased sialic acid content that is probably responsible for its defective fibrin monomer polymerization. An R-type B1γ-binding protein with increased sialic acid content has also been described in patients with hepatoma. Further studies are necessary to determine the mechanism whereby the carbohydrate content of these plasma glycoproteins is altered in patients with liver disease.

ACKNOWLEDGMENT

The authors wish to thank Rosemarie T. Spinella and Andrew Likens for their expert help in the preparation of this manuscript.

REFERENCES

18. Watt KWK, Takagi T, Doolittle RF: Amino acid sequence of...
the β chain of human fibrinogen: Homology with the γ chain. Proc Natl Acad Sci USA 75:1731, 1978


The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains

J Martinez, KA MacDonald and JE Palascak